Xenon Pharmaceuticals (XENE) 10-Q 3 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Oct. 28, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Xenon Pharmaceuticals Inc.
Document Type	10-Q
Trading Symbol	XENE
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		17,893,304
Amendment Flag	false
Entity Central Index Key	1,582,313
Entity Filer Category	Accelerated Filer
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3

Balance Sheets (Unaudited)

Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 54,135	$ 58,651
Marketable securities	15,356
Accounts receivable	595	315
Prepaid expenses and other current assets	1,264	1,900
Total current assets	71,350	60,866
Prepaid expenses, long term	479	1,094
Property, plant and equipment, net	1,542	1,989
Total assets	73,371	63,949
Current liabilities:
Accounts payable and accrued expenses (note 6)	3,976	2,625
Deferred revenue		157
Total current liabilities	3,976	2,782
Deferred tenant inducements	86	133
Total liabilities	4,062	2,915
Shareholders’ equity:
Common shares, without par value; unlimited shares authorized; issued and outstanding: 17,892,933 (December 31, 2015 - 14,385,336)	172,886	148,634
Additional paid-in capital	34,117	33,083
Accumulated deficit	(136,704)	(119,693)
Accumulated other comprehensive loss	(990)	(990)
Shareholders' equity	69,309	61,034
Total liabilities and shareholders’ equity	73,371	63,949
Commitments and contingencies (note 9)

Balance Sheets (Unaudited) (Par

Balance Sheets (Unaudited) (Parenthetical) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Common shares, without par value
Common shares, shares authorized	Unlimited	Unlimited
Common shares, Issued	17,892,933	14,385,336
Common shares, Outstanding	17,892,933	14,385,336

Statements of Operations and Co

Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue:
Collaboration revenue (note 8)	$ 412	$ 4,293	$ 1,393	$ 12,347
Royalties	1	1	34	3
Revenues	413	4,294	1,427	12,350
Operating expenses:
Research and development	5,965	3,793	15,432	10,889
General and administrative	1,779	1,321	5,350	8,219
Total operating expenses	7,744	5,114	20,782	19,108
Loss from operations	(7,331)	(820)	(19,355)	(6,758)
Other income (expense):
Interest income	114	130	336	445
Foreign exchange gain (loss)	(497)	(3,137)	2,026	(5,502)
Net loss and comprehensive loss	$ (7,714)	$ (3,827)	$ (16,993)	$ (11,815)
Net loss per common share (note 4):
Basic and diluted	$ (0.51)	$ (0.27)	$ (1.16)	$ (0.83)
Weighted-average common shares outstanding (note 4):
Basic and diluted	15,268,964	14,298,612	14,690,357	14,251,006

Statement of Shareholders' Equi

Statement of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total		Common Shares [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	[1]
Balance at Dec. 31, 2014	$ 72,779		$ 147,157	$ 30,346	$ (103,734)	$ (990)
Balance (in Shares) at Dec. 31, 2014			14,181,333
Net loss	(15,752)				(15,752)
Stock option compensation expense	2,077			2,077
Issued pursuant to exercise of stock options	278		$ 1,477	(992)	(207)
Issued pursuant to exercise of stock options (in Shares)			204,003
Fair value adjustment upon reclassification of stock options	1,652			1,652
Balance at Dec. 31, 2015	61,034		$ 148,634	33,083	(119,693)	(990)
Balance (in Shares) at Dec. 31, 2015			14,385,336
Net loss	(16,993)				(16,993)
Issuance of common shares,net of issuance costs (note 7a)	23,832		$ 23,832
Issuance of common shares, net of issuance costs (note 7a) (in Shares)			3,450,000
Stock option compensation expense	1,638			1,638
Issued pursuant to exercise of stock options	$ 84		$ 420	(318)	(18)
Issued pursuant to exercise of stock options (in Shares)	72,541	[2]	57,597
Fair value adjustment upon reclassification of stock options	$ (286)			(286)
Balance at Sep. 30, 2016	$ 69,309		$ 172,886	$ 34,117	$ (136,704)	$ (990)
Balance (in Shares) at Sep. 30, 2016			17,892,933
[1]	Our accumulated other comprehensive loss is entirely related to historical cumulative translation adjustments from the application of U.S. dollar reporting when the functional currency of the Company was the Canadian dollar.
[2]	During the nine months ended September 30, 2016, 30,176 stock options were exercised for the same number of common shares for cash (nine months ended September 30, 2015 – 62,469). In the same period, the Company issued 27,421 common shares (nine months ended September 30, 2015 – 100,465) for the cashless exercise of 42,365 stock options (nine months ended September 30, 2015 – 147,381).

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating activities:
Net loss	$ (16,993)	$ (11,815)
Items not involving cash:
Depreciation and amortization	698	754
Stock-based compensation	1,642	3,255
Deferred tenant inducements	(47)	(47)
Unrealized foreign exchange (gain) loss	(2,011)	5,486
Changes in operating assets and liabilities:
Accounts receivable	(272)	(61)
Prepaid expenses, and other current assets	1,251	(1,385)
Accounts payable and accrued expenses	992	223
Deferred revenue	(157)	(9,266)
Net cash used in operating activities	(14,897)	(12,856)
Investing activities:
Purchases of property, plant and equipment	(251)	(408)
Purchase of marketable securities	(15,365)
Proceeds from marketable securities		10,745
Net cash provided by (used in) investing activities	(15,616)	10,337
Financing activities:
Issuance of common shares pursuant to exercise of stock options	84	240
Issuance of common shares, net of issuance costs (note 7a)	23,832
Net cash provided by financing activities	23,916	240
Effect of exchange rate changes on cash and cash equivalents	2,081	(4,278)
Decrease in cash and cash equivalents	(4,516)	(6,557)
Cash and cash equivalents, beginning of period	58,651	72,026
Cash and cash equivalents, end of period	54,135	65,469
Supplemental disclosures:
Interest received	261	550
Supplemental disclosures of non-cash transactions:
Fair value of options exercised on a cashless basis	$ 168	$ 544

Nature of the Business

Nature of the Business	9 Months Ended
	Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of the business	1. Nature of the business: Xenon Pharmaceuticals Inc. (the “Company”), incorporated in 1996 under the British Columbia Business Corporations Act and continued federally in 2000 under the Canada Business Corporation Act, is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own, and for larger market indications that it intends to partner with global pharmaceutical companies.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of presentation	2. Basis of presentation: These financial statements are presented in U.S. dollars. The accompanying unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, these financial statements do not include all of the information and footnotes required for complete financial statements and should be read in conjunction with the audited financial statements and notes for the year ended December 31, 2015 and included in the Company’s 2015 Annual Report on Form 10-K filed with the SEC on March 8, 2016. These unaudited interim financial statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and nine month periods ended September 30, 2016 and 2015 are not necessarily indicative of results that can be expected for a full year. These unaudited interim financial statements follow the same significant accounting policies as those described in the notes to the audited financial statements of the Company included in the Company’s 2015 Annual Report on Form 10-K for the year ended December 31, 2015, except as described below.

Future Changes in Accounting Po

Future Changes in Accounting Policies	9 Months Ended
	Sep. 30, 2016
Accounting Changes And Error Corrections [Abstract]
Future changes in accounting policies	3. Future changes in accounting policies: In May 2014, the Financial Accounting Standards Board (“FASB”) issued amendments to clarify the principles of recognizing revenue and to develop a common revenue standard that would remove inconsistencies in revenue requirements, leading to improved comparability of revenue recognition practices across entities and industries. The amendments stipulate that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Additional disclosure will also be required about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, the FASB issued an update deferring the effective date of the new revenue standard by one year. The new guidance will be effective for public entities for fiscal years and interim periods within those years, beginning after December 15, 2017 instead of the originally contemplated effective date of December 15, 2016. In March, April and May 2016, the FASB issued amendments to the new revenue standard to clarify the implementation guidance on principal versus agent considerations and identifying performance obligations and licensing as well as to address certain narrow-scope improvements and practical expedients at transition with the same effective date as the new revenue standard. The Company is currently evaluating the new guidance to determine the impact it will have on the Company’s financial statements. In February 2016, the FASB issued amendments to lease accounting requiring the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous U.S. GAAP. The new guidance retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. These amendments will be effective for public entities for fiscal years and interim periods within those years, beginning after December 15, 2018. The Company is currently evaluating the new guidance to determine the impact it will have on the Company’s financial statements. In March 2016, the FASB issued amendments to stock-based compensation accounting to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification of the statement of cash flows. The amendments stipulate (a) all excess tax benefits and tax deficiencies should be recognized as income tax expense or benefit in the statement of operations and the tax effects of exercised or vested awards should be treated as discrete items in the reporting period in which they occur, (b) excess tax benefits should be classified along with other tax cash flows as an operating activity, (c) an entity can make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest (current GAAP) or account for forfeitures when they occur, (d) the threshold to qualify for equity classification permits withholding up to the maximum statutory tax rates in the applicable jurisdictions, and (e) cash paid by an employee when directly withholding shares for tax withholding purposes should be classified as financing activity. These amendments will be effective for public entities for fiscal years and interim periods within those years, beginning on or after December 15, 2016 and early adoption is permitted. The Company has early adopted all of the provisions of this update effective January 1, 2016. The Company has elected to recognize forfeitures as they occur and the impact of that change in accounting policy as well as the impact of the remaining provisions did not have a material impact on the Company’s financial statements.

Net Income (Loss) Per Common Sh

Net Income (Loss) Per Common Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Net income (loss) per common share	4. Net income (loss) per common share: Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per common share is computed by adjusting the numerator and denominator of the basic net income (loss) per share calculation for the potential impact of dilutive securities. For the three and nine months ended September 30, 2016 and 2015, all stock options were anti-dilutive and were excluded from the diluted weighted average common shares outstanding for those periods.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair value of financial instruments	5. Fair value of financial instruments: We measure certain financial instruments and other items at fair value. To determine the fair value, we use the fair value hierarchy for inputs used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority). • Level 1 - Unadjusted quoted prices in active markets for identical instruments. • Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). • Level 3 - Inputs are unobservable and reflect the Company’s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s Level 1 assets include cash and cash equivalents and marketable securities with quoted prices in active markets. The carrying amount of accounts receivables, accounts payable and accrued expenses approximates fair value due to the nature and short-term of those instruments. Liability classified stock options have been valued using a Black-Scholes pricing model to estimate fair value using Level 3 inputs as defined above, as quoted prices are not readily available.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2016
Payables And Accruals [Abstract]
Accounts payable and accrued expenses	6. Accounts payable and accrued expenses: Accounts payable and accrued expenses consisted of the following: September 30, December 31, 2016 2015 Trade payables $ 512 $ 1,088 Employee compensation, benefits, and related accruals 993 762 Consulting and contracted research 1,901 506 Professional fees 544 214 Other 26 55 Total $ 3,976 $ 2,625

Share Capital

Share Capital	9 Months Ended
	Sep. 30, 2016
Stockholders Equity Note [Abstract]
Share Capital	7. Share Capital (a) Financing: On September 13, 2016, the Company completed an underwritten public offering of 3,450,000 of its common shares at a public offering price of $7.50 per common share. The Company received approximately $24.3 million of proceeds, net of underwriting discounts and commissions but before offering expenses. (b) Stock option plan: The following table presents stock option activity for the period: Three Nine 2016 2015 2016 2015 Outstanding, beginning of period 1,983,674 1,745,018 1,721,472 1,484,218 Granted 22,044 4,100 321,444 384,538 Exercised (1) (42,012 ) (110,039 ) (72,541 ) (209,850 ) Forfeited and expired (4,753 ) (1,905 ) (11,422 ) (21,732 ) Outstanding, end of period 1,958,953 1,637,174 1,958,953 1,637,174 Exercisable, end of period 1,200,614 1,052,955 1,200,614 1,052,955 (1) The fair value of each option granted to employees and non-employees is estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Average risk-free interest rate 1.33 % 1.74 % 1.58 % 1.71 % Average expected term (in years) 6.19 6.25 6.22 6.23 Expected volatility 75 % 67 % 75 % 75 % Expected dividend yield 0.00 % 0.00 % 0.00 % 0.00 % The weighted-average fair value of options granted during the nine months ended September 30, 2016 was $4.93 (nine months ended September 30, 2015 – $11.50) per option .

Collaboration Agreements

Collaboration Agreements	9 Months Ended
	Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaboration agreements	8. Collaboration agreements: The Company has entered into a number of collaboration agreements with multiple deliverables under which it may have received non-refundable upfront payments. The Company generally recognizes revenue from upfront payments ratably over the term of its estimated period of performance of research under its collaboration agreements in the event that such arrangements represent a single unit of accounting. The collaborations may also include contractual milestone payments, which relate to the achievement of prespecified research, development, regulatory and commercialization events. The milestone events coincide with the progression of product candidates from research and development, to regulatory approval and through to commercialization. The process of successfully discovering a new product candidate, having it selected by the collaborator for development and having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments that the Company may earn from its collaborators involve a significant degree of risk to achieve. The following table is a summary of the revenue recognized from the Company’s collaborations for the three and nine months ended September 30, 2016 and 2015: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Teva: Recognition of upfront payment $ — $ 2,940 $ — $ 8,724 Research funding 29 11 87 101 Genentech: Recognition of upfront payment — 182 157 542 Research funding 383 910 1,149 2,730 Milestone payment — 250 — 250 Total collaboration revenue $ 412 $ 4,293 $ 1,393 $ 12,347

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and contingencies: (a) Priority access agreement with Medpace Inc. (“Medpace”): In August 2015, the Company entered into a priority access agreement with Medpace for the provision of certain clinical development services. Under the terms of the agreement, the Company has committed to using Medpace non-exclusively for clinical development services over the five year term of the agreement. In consideration for priority access to Medpace resources and preferred service rates, the Company has committed to $7,000 of services over the term of the agreement, $3,000 of which was paid in the year ended December 31, 2015. Of the amounts paid by the Company in 2015 in connection with the priority access agreement, $2,013 has been recorded as expenses to date for services rendered, $508 has been recorded as current prepaid expenses (December 31, 2015 – $1,010) and $479 as long-term prepaid expenses (December 31, 2015 – $1,094) for the provision of future services as at September 30, 2016. (b) Guarantees and indemnifications: The Company has entered into license and research agreements with third parties that include indemnification provisions that are customary in the industry. These indemnification provisions generally require the Company to compensate the other party for certain damages and costs incurred as a result of third party claims or damages arising from these transactions. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds commercial and product liability insurance. This insurance limits the Company’s exposure and may enable it to recover a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and the Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.

Accounts Payable and Accrued 16

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2016
Payables And Accruals [Abstract]
Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following: September 30, December 31, 2016 2015 Trade payables $ 512 $ 1,088 Employee compensation, benefits, and related accruals 993 762 Consulting and contracted research 1,901 506 Professional fees 544 214 Other 26 55 Total $ 3,976 $ 2,625

Share Capital (Tables)

Share Capital (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Option Activity	The following table presents stock option activity for the period: Three Nine 2016 2015 2016 2015 Outstanding, beginning of period 1,983,674 1,745,018 1,721,472 1,484,218 Granted 22,044 4,100 321,444 384,538 Exercised (1) (42,012 ) (110,039 ) (72,541 ) (209,850 ) Forfeited and expired (4,753 ) (1,905 ) (11,422 ) (21,732 ) Outstanding, end of period 1,958,953 1,637,174 1,958,953 1,637,174 Exercisable, end of period 1,200,614 1,052,955 1,200,614 1,052,955 (1)
Fair Value Assumptions for Stock Options	The fair value of each option granted to employees and non-employees is estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Average risk-free interest rate 1.33 % 1.74 % 1.58 % 1.71 % Average expected term (in years) 6.19 6.25 6.22 6.23 Expected volatility 75 % 67 % 75 % 75 % Expected dividend yield 0.00 % 0.00 % 0.00 % 0.00 %

Collaboration Agreements (Table

Collaboration Agreements (Tables)	9 Months Ended
	Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Revenues from Collaborations	The following table is a summary of the revenue recognized from the Company’s collaborations for the three and nine months ended September 30, 2016 and 2015: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Teva: Recognition of upfront payment $ — $ 2,940 $ — $ 8,724 Research funding 29 11 87 101 Genentech: Recognition of upfront payment — 182 157 542 Research funding 383 910 1,149 2,730 Milestone payment — 250 — 250 Total collaboration revenue $ 412 $ 4,293 $ 1,393 $ 12,347

Accounts Payable and Accrued 19

Accounts Payable and Accrued Expenses - Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Trade payables	$ 512	$ 1,088
Employee compensation, benefits, and related accruals	993	762
Consulting and contracted research	1,901	506
Professional fees	544	214
Other	26	55
Total	$ 3,976	$ 2,625

Share Capital (Details)

Share Capital (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 13, 2016	Sep. 30, 2016	Sep. 30, 2015
Class Of Stock [Line Items]
Proceeds from net of underwriting discounts and commissions Before offering expenses		$ 23,832
Weighted-average fair value of options granted		$ 4.93	$ 11.50
Underwritten Public Offering [Member]
Class Of Stock [Line Items]
Issuance of common shares, net of issuance costs (in Shares)	3,450,000
Common share price (in Dollars per share)	$ 7.50
Proceeds from net of underwriting discounts and commissions Before offering expenses	$ 24,300

Share Capital - Stock Option Ac

Share Capital - Stock Option Activity (Details) - shares		3 Months Ended		9 Months Ended		12 Months Ended
		Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Outstanding, beginning of period		1,983,674	1,745,018	1,721,472	1,484,218	1,484,218
Granted		22,044	4,100	321,444	384,538
Exercised	[1]	(42,012)	(110,039)	(72,541)	(209,850)
Forfeited and expired		(4,753)	(1,905)	(11,422)	(21,732)
Outstanding, end of period		1,958,953	1,637,174	1,958,953	1,637,174	1,721,472
Exercisable, end of period		1,200,614	1,052,955	1,200,614	1,052,955
[1]	During the nine months ended September 30, 2016, 30,176 stock options were exercised for the same number of common shares for cash (nine months ended September 30, 2015 – 62,469). In the same period, the Company issued 27,421 common shares (nine months ended September 30, 2015 – 100,465) for the cashless exercise of 42,365 stock options (nine months ended September 30, 2015 – 147,381).

Share Capital - Stock Option 22

Share Capital - Stock Option Activity (Parenthetical) (Details) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Options exercised for Number of Common Shares for cash	30,176	62,469
Common stock issued for cashless exercise	27,421	100,465
Cashless exercise of stock options	42,365	147,381

Share Capital - Fair Value Assu

Share Capital - Fair Value Assumptions for Stock Options (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Fair Value Assumptions For Stock Options [Abstract]
Average risk-free interest rate	1.33%	1.74%	1.58%	1.71%
Average expected term (in years)	6 years 2 months 9 days	6 years 3 months	6 years 2 months 19 days	6 years 2 months 23 days
Expected volatility	75.00%	67.00%	75.00%	75.00%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Collaboration Agreements - Reve

Collaboration Agreements - Revenue Recognized from Collaborations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Collaboration Revenue [Line Items]
Collaboration revenue	$ 412	$ 4,293	$ 1,393	$ 12,347
Teva [Member] | Recognition of Upfront Payment [Member] | Collaborative Arrangement [Member]
Collaboration Revenue [Line Items]
Collaboration revenue		2,940		8,724
Teva [Member] | Research Funding [Member] | Collaborative Arrangement [Member]
Collaboration Revenue [Line Items]
Collaboration revenue	29	11	87	101
Genentech [Member] | Recognition of Upfront Payment [Member] | Collaborative Arrangement [Member]
Collaboration Revenue [Line Items]
Collaboration revenue		182	157	542
Genentech [Member] | Research Funding [Member] | Collaborative Arrangement [Member]
Collaboration Revenue [Line Items]
Collaboration revenue	$ 383	910	$ 1,149	2,730
Genentech [Member] | Milestone Payment [Member] | Collaborative Arrangement [Member]
Collaboration Revenue [Line Items]
Collaboration revenue		$ 250		$ 250

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Aug. 31, 2015
Unrecorded Unconditional Purchase Obligation [Line Items]
Prepaid expenses, long term	$ 479	$ 1,094
Medpace Clinical Development Service Agreement [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Service agreement, term	5 years
Committed service obligation			$ 7,000
Contractual obligation paid		3,000
Expenses for services rendered	$ 2,013
Current prepaid expenses	508	1,010
Prepaid expenses, long term	$ 479	$ 1,094